Understanding the Geographic Atrophy Journey: Patient and Physician Perspectives to Inform Better Care Authors: Lynn Baker, Firas M. Rahhal, Christopher J. Gilbert, Theodore Leng Published: 2026 ABSTRACT ObjectivesGeographic atrophy (GA) can place substantial physical and emotional burdens on affected individuals, related to both the disease and its treatment. Here, we provide insights into the perspectives of a patient with GA and retina specialists around GA diagnosis, treatment, communication, and needs.MethodsUnstructured qualitative interviews were conducted with a patient author with GA and two retina specialist authors involved in the management of GA. The authors discussed early GA symptoms, its diagnosis and management, treatment experience, support, and education.ResultsSeveral themes emerged. A GA diagnosis can be emotionally distressing and difficult for patients to accept. The reality is that although current treatments delay progression of further visual impairments, these therapies do not restore lost vision. Current GA treatments are associated with frequent clinic visits and intravitreal injections that can lead to discomfort and temporary visual disturbances, which are disruptive to daily life. Physicians also noted a lack of clinical endpoints for guiding optimal dosing. The importance of patient–physician communication in the management of GA was highlighted, focusing on an approach that incorporates the emotional and practical needs of patients. Physicians play a central role in ensuring treatment compliance to minimize further vision loss. Peer support is also invaluable for sharing experiences, treatment expectations, and reassurance. Finally, patient and provider suggestions for improving outcomes for people with GA were discussed, including access to patient-focused educational materials on GA and treatment, development of tangible endpoints in clinical trials, and facilitation of peer support. All authors supported the development of long-acting formulations, systemic medications, or optimally a cure, to reduce treatment burden.ConclusionsGA and its treatment place a substantial burden on patients. Multiple opportunities remain to improve the experiences of people with GA and empower patients to understand their condition and treatment, which ultimately could improve their outcomes.Audio feature available for this article.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s40123-026-01459-1. Key Summary Points Geographic atrophy (GA) is a type of dry age-related macular degeneration that results in progressive, permanent vision loss.Diagnosis methods are not standardized, leading to delays in treatment initiation.Recently approved treatments provide some benefit but require monthly intraocular injections that can affect activities of daily living.In this article, a patient and two retinal specialists provide insights into patient and physician experiences around diagnosing, managing, and living with GA.Multiple opportunities to improve the disease- and treatment-related burdens faced by people with GA are discussed. Geographic atrophy (GA) is a type of dry age-related macular degeneration that results in progressive, permanent vision loss.Diagnosis methods are not standardized, leading to delays in treatment initiation.Recently approved treatments provide some benefit but require monthly intraocular injections that can affect activities of daily living.In this article, a patient and two retinal specialists provide insights into patient and physician experiences around diagnosing, managing, and living with GA.Multiple opportunities to improve the disease- and treatment-related burdens faced by people with GA are discussed. Digital Features This article is published with digital features, including an audio feature and the accompanying transcript, to facilitate understanding of the article. To view digital features for this article, go to https://doi.org/10.6084/m9.figshare.32881793. Introduction Geographic atrophy (GA) represents an advanced form of dry age-related macular degeneration (AMD), which is a leading cause of blindness [1, 2]. GA affects the outermost layers of the retina and is characterized by progressive loss of photoreceptor cells and retinal pigment epithelium (RPE) cells, along with reduced vessel density in the choriocapillaris [2]. As a result, people with GA experience gradual and permanent vision loss [2]. The prevalence of GA in the United States has been estimated at around 0.5% [1, 3]. However, GA prevalence increases with age and given an aging population worldwide, GA has become a considerable cause of visual impairment [1]. Until recently, no treatment options were available for GA. In 2021 and 2023, two complement inhibitors, pegcetacoplan and avacincaptad pegol, were approved by the US Food and Drug Administration (FDA) for the treatment of GA secondary to AMD, respectively [4–7]. These approvals are based on clinical trials demonstrating their potential to slow GA growth, but not improve visual acuity [8–10]. Both medications are administered via intravitreal injection. Despite these advances, there is currently no standardized process for the identification and diagnosis of GA [11]. Furthermore, GA represents a substantial clinical, emotional, and financial burden for people living with the disease and their caregivers, with considerable impacts on activities of daily living as well as on psychological and emotional well-being [12]. GA is associated with a reduced vision-related quality of life (QoL) and notable healthcare resource use-associated costs [13]. Given the challenges of living with and managing GA, it is important to gain insights from patients and treating physicians on their experiences around diagnosis, treatment, and the impact of GA, to inform improvements in patient care. In this work, interviews with a patient (author LB) and retina specialists (authors FMR and TL) provide insights into their experiences of GA and their perspectives on how GA care could be improved. See Audio Feature 1 in the online/HTML version of the manuscript or follow the digital features link under the abstract to directly hear the patient’s perspective. Audio Feature 1. Living with geographic atrophy: the patient’s story. An interview with the lead author on her experiences and perspective on what still needs to be done to improve patients’ lives. Transcript available in Appendix 1. Supplementary file3 (MP4 45297 KB) Audio Feature 1. Living with geographic atrophy: the patient’s story. An interview with the lead author on her experiences and perspective on what still needs to be done to improve patients’ lives. Transcript available in Appendix 1. Supplementary file3 (MP4 45297 KB) Methods Moderated, guided interviews with the authors were performed by FMR and TL (interviewing LB), and Jun Zhang (a study sponsor, interviewing FMR and TL). The patient (LB) and retina specialists (FMR and TL) were asked predetermined questions about early signs and symptoms, diagnosis, management, treatment experience, support, and education. Responses were recorded and summarized by a medical writer. Ethical Approval Institutional Review Board/ethics committee approval was not applicable for this publication, as all interviewees are authors of this publication, and the article does not contain any new studies with human participants or animals. The interviews were conducted in compliance with the Helsinki Declaration of 1964 [14] and its later amendments. Informed consent was provided by all authors to publish the findings from their interviews; author LB provided an artwork release agreeing to publication of images painted by her in Figs. 1 and 3.Fig. 1Artwork by the author LB has provided a means of communicating her experiences of GA symptoms. The images depict what faces look like when the viewer lacks central vision, and all show the absence, or distortion, of the subject’s eyes, themselves. A Depiction of a face with one eye and no pupil. B Depiction of a face with no eyes. C Depiction of what it is like to see a face “melt.” Images courtesy of Dr Lynn Baker Artwork by the author LB has provided a means of communicating her experiences of GA symptoms. The images depict what faces look like when the viewer lacks central vision, and all show the absence, or distortion, of the subject’s eyes, themselves. A Depiction of a face with one eye and no pupil. B Depiction of a face with no eyes. C Depiction of what it is like to see a face “melt.” Images courtesy of Dr Lynn Baker Results Psychological and Practical Challenges of the GA Diagnosis The Patient’s Perspective In October 2021, LB was informed that she would lose vision in one eye. This was emotionally devastating for LB, who was a retired physician. She already had an awareness of GA, as her father experienced GA-related vision loss, resulting in very limited peripheral vision by the end of his life. LB’s experiences with her father told her it would not be an easy road ahead. Approximately 20 years earlier, LB attended annual ophthalmologist check-ups based on recommendations for routine eye care [11], and it was at these check-ups that drusen and signs of early AMD were observed by her ophthalmologist. However, the disease did not worsen for over a decade. LB first reported visual symptoms about 16 years after her AMD diagnosis, noticing wavy lines on an Amsler grid. Later, while playing Sudoku on her smartphone, the lines appeared wavy, and the numbers were blurred. LB is a keen artist and enjoys painting as a hobby. Although her GA symptoms began to make painting more difficult, LB found it to be a valuable way to pay close attention to visual changes, as well as a means of expressing her experiences with GA (Fig. 1) and providing comfort in meeting and socializing with others. As LB’s visual symptoms worsened, she was referred to a retina specialist (author FMR). At first, LB struggled to cope with her GA diagnosis. However, proactively researching future lifestyle changes, including the possibility of assisted living and the use of assistance dogs, helped her to come to terms with the substantial challenges she would likely face. Although the diagnosis was overwhelming, LB approached the situation pragmatically and furthered her education on GA by researching Internet-based resources. These included the National Institutes of Health (NIH; see Age-Related Macular Degeneration: What You Should Know at https://www.nei.nih.gov/sites/default/files/health-pdfs/nei_wysk_amd.PDF) and Mayo Clinic (see Geographic atrophy—Symptoms and causes—Mayo Clinic and Geographic atrophy—Diagnosis and treatment—Mayo Clinic). Her own professional background as a physician helped inform her where to look for trusted information. The Physician’s Perspective Current diagnostic practice typically performed by FMR and TL includes retinal examinations, optical coherence tomography (OCT), and imaging techniques such as infrared and fundus autofluorescence. Both specialists emphasized the critical importance of OCT in detecting early signs of conversion to neovascular AMD (nAMD). However, current methods have limitations. TL has noted discrepancies between anatomic findings and visual acuity assessments, which fail to capture the real-world burden as described by patients with GA. Patients may have difficulty with seeing faces, reading whole words rather than the single letters used in visual acuity assessments, and performing fine motor tasks like sewing. Looking ahead, FMR and TL recognize the potential of advances in imaging and artificial intelligence tools to enable better visualization of the penumbra area and prediction of the direction of lesion growth. Such powerful tools would enable more precise monitoring and demonstrate treatment effectiveness to patients. In addition, physicians face broader challenges related to communicating the GA diagnosis and monitoring the effect of GA and its treatment on QoL. Historically, before the availability of intravitreal complement inhibitors, physicians had no treatment options for GA. TL described a sense of dread when meeting patients with GA, as the absence of effective treatment contributed to feelings of being powerless to help patients. Even with the availability of complement inhibitors, physicians can find it difficult to explain to patients that their vision will not improve, since the available treatments merely slow GA progression rather than stop or even reverse vision loss. GA Treatment Challenges The Patient’s Perspective Complement inhibitors were not available at the time of LB’s diagnosis, and she was not eligible for a clinical trial. After approval by the FDA, LB commenced treatment with a market-authorized drug for this indication, appreciating the availability of a new therapeutic option where none had existed previously. Thanks in part to her training as a physician, she was able to understand the nuances of GA, ask questions about her treatment plan, and communicate her experiences with treatment openly with FMR. Since initiating treatment with this drug, LB’s GA has remained stable, and she has even noticed some unexplained improvements in vision, even though the therapy is intended to slow disease progression rather than restore vision. Despite the benefits of the new treatment options for GA, LB’s experiences of receiving intravitreal injections highlight the burden of current GA treatment (Fig. 2). LB described the experience of the intravitreal injection as “weird” and emotionally draining. She feels pressure on her eye during the injection procedure, followed by an explosion of gel into the eye, which at times resembles an inverted mushroom cloud. This injection can form large bubbles of white surrounded by black throughout her field of vision (except in the blind spot), which may obscure vision (Fig. 3). In fact, one such bubble from the initial injection has remained in her eye, although those from subsequent injections have since disappeared. LB has found the overall experience difficult to explain, but she likened it to hallucinations that continued for two weeks post-injection.Fig. 2Patient-reported burden of current injectable treatments for GA. GA geographic atrophyFig. 3LB’s experience of bubbles after her first injection, as captured in her artwork. LB uses painting to visually communicate her experiences of treatment. Image courtesy of Dr. Lynn Baker Patient-reported burden of current injectable treatments for GA. GA geographic atrophy LB’s experience of bubbles after her first injection, as captured in her artwork. LB uses painting to visually communicate her experiences of treatment. Image courtesy of Dr. Lynn Baker The monthly injections affect LB’s daily activities and require LB to change her daily routines. The bubbles obscuring her vision mean that she cannot drive herself home from the clinic after the injection. This has an effect on her friends and family, who must take time out of their schedules to help transport her from the clinic. Recovery from each administration requires an entire day and affects her daily activities. Consequently, LB schedules the appointments in the morning and spends the rest of the day recovering and listening to audiobooks. Even this activity presents a challenge, as it is difficult for her to see what books she is choosing on her screen or even to find and press the “play” button. LB is required to schedule her entire life around her injection days. After the injection, she must spend a week monitoring for adverse events (such as an infection or sudden switch to nAMD), during which time she cannot travel as she must have immediate access to FMR in case of emergency. This leaves only 3 weeks per month for LB to fully live her life. In terms of future planning, LB and FMR have discussed a treatment plan in the event of visual deterioration, but they agreed that they will have to wait for better treatment options to become available. The intravitreal complement inhibitors have provided LB with clinical benefit to which she would not have otherwise had access due to a lack of alternative treatment options. Nevertheless, LB is hopeful for medications that can be delivered more easily than intravitreal injection, such as oral medications, that could reduce the treatment burden. The ultimate aim of treatment for LB would be a cure, such as macular replacement therapy. The Physician’s Perspective FMR pointed out that when treating patients with pegcetacoplan or avacincaptad pegol, he mostly adheres to the label recommendations owing to a paucity of clinical endpoints that can be used to guide optimal dosing [6, 7]. He uses a fixed-interval monthly or once-every-two-month dosing regimen for pegcetacoplan, and a monthly dosing regimen for avacincaptad pegol for the first few months, followed by reduction to every two months. This contrasts with his approach to treating patients with diabetic macular edema and nAMD, which both involve treat-and-extend regimens (or as-needed regimens for patients able to maintain longer treatment intervals). FMR and TL agreed that it is crucial that physicians set expectations with their patients about GA progression and treatment. Physicians should make it clear that the current complement inhibitor treatment options for GA cannot bring back vision that is already lost. In addition, physicians should ensure that their patients understand that these therapies require lifelong administration of regular injections. TL noted that physicians must effectively communicate to their patients what to expect with complement inhibitor injections. Although LB discusses her experiences with FMR, other people with GA may be unlikely to do so. Physicians need to consider the experience of receiving an injection from their patient’s point of view, as well as inform patients about the unpredictability of the sensations and visual effects of each administration. Effective communication between physician and patient extends beyond the treatment experience. The strong patient–physician relationship between LB and FMR empowered LB to request changing her dosing interval from bimonthly to monthly. This exemplifies the power of an effective patient–physician relationship, which enables the patient to understand their disease and participate in treatment decisions, which could in turn improve outcomes. Both retina specialists acknowledged that new therapies for GA are needed. Both believe that potent efficacy to improve vision is the most important consideration for new therapies. Second only to efficacy is the need for easier administration of new therapies compared with current options. For instance, treatments with extended durability between administrations, and those with lower viscosity and thus, thinner needles, would improve upon current treatment options. Support and Education Requirements The Role of the Physician There was consensus between the patient and physician authors that physicians and other healthcare professionals (HCPs) play a key role in motivating patients to attend clinic appointments and adhere to treatment regimens, thereby maximizing clinical benefits and minimizing further vision loss. This is particularly crucial because nonadherence to treatment among patients receiving intravitreal injections is common and has been reported to be as high as 95% among patients with nAMD [15]. Trust between physicians and patients is one of the biggest motivators in achieving good adherence to treatment [15, 16]. In fact, FMR finds that a positive patient experience at clinics can be a strong motivating factor. In contrast, the fear of losing their vision is a strong motivator for some people; however, FMR cautioned against exploiting that fear to encourage treatment adoption, as it can cause undue distress for some people. Instead, LB advised that HCPs should tailor their approach to each individual with GA, as motivational factors are highly personal. The Role of Online Tools and Peer Support The patient and physician authors all recognize that people living with GA need access to patient-focused, succinct, accurate, and appropriate information that explains the natural history and progression of AMD to GA, and stresses the importance of adherence to regular injections to limit further vision loss. In addition to the aforementioned NIH and Mayo Clinic resources, other online information sources can be found from the Macular Society https://www.macularsociety.org/macular-disease/macular-conditions/dry-age-related-macular-degeneration/geographic-atrophy/ and from treatment centers. Peer support can be invaluable to people with GA. In LB’s experience, other people with GA have not always been informed by their physicians about treatment options. She therefore offers advice and support to others living with GA. Conversations between people with GA undergoing intravitreal injections enable the sharing of experiences and the reassurance to others that their experiences are valid and normal. Therefore, a need exists to empower people living with GA to meet and share their experiences with their peers. The Promise of Future Therapies People with GA may be encouraged to know that new and better therapeutic options could be available in the future. Several potential therapeutic approaches are under investigation for GA, summarized in Table S1. Investigational approaches include gene, stem cell, oral, and biologic therapies. Gene therapies include those targeting the complement cascade. Another gene therapy approach aims to re-express retinoic acid receptor-related orphan receptor A (RORα), a nuclear receptor shown to negatively regulate pathological neovascularization and inflammation in the choroid/RPE complex. Single-nucleotide polymorphisms of RORα have been linked to AMD [2]. Gene therapies would have the advantage over other therapies in that they would only require a single injection. Stem cell therapy has the potential to improve vision, rather than merely slow progression as per current therapy options. Many ongoing trials of stem cell therapies involve RPE cells and would only require a single procedure. Additionally, authors FMR and TL are actively involved in stem cell replacement trials for GA. Biologic therapies, including monoclonal antibodies, peptides, and small interfering RNA, are also under evaluation. Some biologics target the complement pathway, building on the progress made on complement inhibition with the currently approved agents for GA. Others aim to improve mitochondrial function or drug penetration. Finally, emerging oral small-molecule therapies may offer a key advantage, eliminating the need for injections entirely. Discussion The interviews with a patient and two treating physicians presented here demonstrate that GA diagnosis and treatment present major challenges. They also reveal that strong patient–physician communication is vital and that future therapies currently in development may help to improve the patient experience with GA. Many perspectives shared by patient and physician authors here are reflected in scientific literature [11, 17, 18]. The retina specialists’ approach to GA diagnosis correlates with expert recommendations, in which OCT is the preferred imaging method to identify GA owing to its ease of use and accessibility among ophthalmologists [11]. When managing GA, the discrepancies noted by FMR and TL between clinical assessments and patient-reported vision changes have been recognized elsewhere. Visual acuity tests do not necessarily capture the whole range of symptoms people with GA may experience [17, 18]. Estimating any beneficial effects of new GA treatments has also proved challenging. There has been discordance between clinical trial endpoints in the GA treatment trials in that positive anatomic outcomes were not reflected in changes in visual function measures [19]. LB welcomed the two new treatment options now available for GA and looks forward to more treatment options becoming available in the future, should her vision deteriorate further. Similarly, responses to a survey of 203 people with GA before avacincaptad pegol and pegcetacoplan were approved showed most were willing to try new treatments to slow disease progression [20]. In addition, the need for better education and support highlighted by the authors is reflected by previous reports describing the need for more educational materials about GA, and for GA-based support groups [20–22]. The strong and trusting relationship between LB and FMR proved to be the ideal model; however, this is relatively rare in clinical practice. A strong patient–physician relationship is valuable to help the physician appreciate the impact of GA, as it has been previously noted that ophthalmologists can underestimate the effect of AMD on QoL [23]. Indeed, surveys have found that people with AMD (including GA) want more support from their HCP [20]. People with AMD have revealed that HCPs provided inadequate information on disease management [22]. From the HCP perspective, appointments can be too short for HCPs to provide detailed communications about GA prognosis [22]. Furthermore, there is a need for physicians to consider their patients holistically and beyond simply treating their disease [18]. In fact, the importance of effective patient–physician communication raised by the authors has been reflected in recommendations for personalized risk–benefit assessments and physician-led patient education with respect to GA progression and treatment expectations [11]. The insights from the authors here highlight unmet clinical needs in GA recognized elsewhere. There is a need for a standardized process to identify and diagnose GA [11]. In addition, current GA treatments slow but do not necessarily reverse GA progression [11], and regular visits for GA treatment administration are required [6, 7, 11]. Furthermore, as pointed out by FMR, there is a need for injectable treatments that are less viscous than those currently available, so thinner needles can be used to reduce pain during injection, increase comfort, and reduce recovery time. The authors’ experiences, borne out by other reports [17, 18, 20, 22], have informed suggestions as to how GA care could be improved (Fig. 4). Central to improvements in GA care is the development of new therapy options.Fig. 4Summary of suggestions to improve GA outcomes, arising from the patient and physician experience of living with GA. AI artificial intelligence, GA geographic atrophy, QoL quality of life Summary of suggestions to improve GA outcomes, arising from the patient and physician experience of living with GA. AI artificial intelligence, GA geographic atrophy, QoL quality of life In conclusion, GA places a substantial burden on people living with the disease. Current treatment options have helped prevent progression of the disease, but these are associated with their own challenges. Therefore, new treatment options are urgently needed that ease the burdensome experience of patients receiving intravitreal injections. Furthermore, there remain multiple opportunities to enhance communication between physicians and people living with GA to meaningfully improve clinical outcomes, empower patients to understand their condition and treatment, and elevate patient QoL. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PDF 167 KB)Supplementary file2 (PDF 155 KB) Supplementary file1 (PDF 167 KB) Supplementary file2 (PDF 155 KB)